Universal access to preventive drugs could reduce HIV incidence in sub-Saharan Africa

February 09, 2021

Universal HIV testing with linkage to treatment and prevention may be a promising approach to accelerate reductions in new infections in generalized epidemic settings, according to a study published February 9th, 2021 in the open-access journal PLOS Medicine by Catherine Koss of the University of California, San Francisco, and colleagues.

Despite major gains in HIV testing and treatment, in 2019 there were 1.7 million new HIV infections, of which nearly 60% occurred in sub-Saharan Africa. Daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine is highly effective for HIV prevention and could substantially reduce new HIV infections if offered alongside access to HIV testing and treatment. But little is known about the incidence of new HIV infections among PrEP users in settings with generalized HIV epidemics, particularly outside of selected risk groups. To address this knowledge gap, Koss and colleagues conducted community-based HIV testing and offered universal access to PrEP in 16 communities in the Sustainable East Africa Research in Community Health (SEARCH) study in rural Kenya and Uganda. They offered rapid or same-day PrEP initiation and flexible service delivery with follow-up visits at facilities or community-based sites over a period of 144 weeks. According to the authors, this study is the first in sub-Saharan Africa to assess HIV incidence after offering PrEP at a population level.

Among 74,541 individuals who tested negative for HIV, 21% were assessed to be at elevated HIV risk, and 5,447 (35%) of those individuals initiated PrEP, with 79% participating in follow-up visits. Over 7,150 person-years of follow-up, HIV incidence was 0.35 per 100 person-years (95% CI 0.22-0.49) among PrEP initiators. Among matched historical controls in 8 of the communities, HIV incidence was 0.92 per 100 person-years (95% CI 0.49-1.41) over the year prior to PrEP availability. Compared to matched historical controls, HIV incidence was 74% lower overall in PrEP initiators in 8 of the communities (adjusted incidence rate ratio [aIRR] 0.26, 95% CI 0.09-0.75; p=0.013), and 76% lower among women (aIRR 0.24, 95% CI 0.07-0.79; p=0.019), but not significantly lower in men. Data on HIV incidence among historical controls were not available for the remaining 8 communities.

Because rates of new HIV infections are higher in women than in men, the results suggest that PrEP may help to close the gender gap in new infections. According to the authors, universal access to HIV testing, treatment, and prevention, including rapid provision of PrEP with flexible service delivery, could reduce HIV incidence in generalized epidemic settings.

Dr. Kamya states "We know that PrEP is highly effective - and now we need systems that make it easier to start and continue taking it. This study showed that providing broad access to PrEP in community-based settings significantly reduced HIV incidence."

Dr. Koss adds "We found that universal HIV testing with easy access to PrEP was associated with lower rates of HIV, particularly among women."
-end-
Research Article

Peer-reviewed; Experimental study; Humans

In your coverage please use this URL to provide access to the freely available paper:
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003492

Funding: Research reported in this manuscript was supported by the Division of AIDS, National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health under award numbers U01AI099959 and UM1AI068636, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), and the Bill & Melinda Gates Foundation under award number OPP1159068. This research was also supported by the U.S. National Institutes of Health under award numbers 2R01AI098472 (to MG for measurement of tenofovir hair concentrations) and K23MH114760 (to CAK). Gilead Sciences donated tenofovir disoproxil fumarate/emtricitabine (Truvada) as study drug. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, PEPFAR, Gates Foundation, or Gilead Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: CAK has received grant support to institution from the US National Institutes of Health and Gilead Research Scholars Program in HIV. DVH has received grant support from the US National Institutes of Health and study drug donation from Gilead Sciences. CM has received grant support from the US National Institutes of Health, the Stupski Foundation, and the Chan-Zuckerberg Biohub Foundation. LiBB has received grant support from the US National Institutes of Health. VJ has received grant support from the US Centers for Disease Control and Prevention/PEPFAR.

Citation: Koss CA, Havlir DV, Ayieko J, Kwarisiima D, Kabami J, Chamie G, et al. (2021) HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. PLoS Med 18(2): e1003492.
https://doi.org/10.1371/journal.pmed.1003492

PLOS

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.